Takeda California Mobilizes to Support Healthy Living and Combat Diabetes

Employees will be biking to raise funds for the American Diabetes Association in both San Diego and San Francisco, March 22.

San Diego, San Francisco, CA, US, March 20, 2012 -- Takeda California scientists and employees are taking a stand for healthy living to combat diabetes and leading by example with a company-wide bike ride. On March 22, the second annual Tour de Takeda will take place in both San Diego and San Francisco, with Takeda California making donations to the American Diabetes Association to match employee’s distance covered.

The festivities kick off in San Diego with employees biking at Fiesta Island in Mission Bay, receiving support for repairs and maintenance from Performance Bikes. In San Francisco, employees will be biking at Coyote Point Recreation Area in South San Francisco.

Takeda’s involvement with social responsibility is part of Takeda’s ongoing dedication and commitment to society through corporate social responsibility activities. Last year, Takeda employee’s involvement and company donations were able to make a huge impact in San Diego and San Francisco for several nonprofits committed to helping youth, fighting cancer, and protecting the environment.

“Our employees are very excited for our second annual Tour de Takeda, making suggestions of their favorite bike trails,” said Keith Wilson, Takeda California President. “Collectively, we have an amazing team of individuals that take pride in aiding our community. Each year we conduct several company-wide efforts to support local nonprofit organizations, schools, and the environment.”

PHOTO OPPORTUNITY: SAN DIEGO: Fiesta Island
SAN FRANCISCO: Coyote Point Recreation Area
WHEN: Thursday, March 22, at 9am-1pm

About Takeda California
Takeda California is Takeda's Center of Excellence and Innovation for Structure-Based Drug Discovery and Protein Therapeutics. The company combines cutting-edge protein x-ray crystallography, small molecule, antibody, and antibody drug-conjugate capabilities to efficiently generate potential new medicines for treating cancer, inflammatory diseases and metabolic diseases. Multiple potential new drugs invented at Takeda California are in clinical trials evaluation including NESINA® (generic name Alogliptin) which was approved for treating patients with type II diabetes in Japan in 2010.
Takeda California is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, one of Japan's largest pharmaceutical companies and one with a 230-year heritage. Together with its worldwide partners in science, Takeda California is committed to strive toward better health for patients through leading innovation in medicine. Additional information about Takeda California is available through its affiliate Web site, http://www.takedacalifornia.com.

About Takeda
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As one of the largest pharmaceutical companies in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate Web site, www.takeda.com.

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals.

Contact :
Jennifer Von Stauffenberg
Olive PR Solutions, Inc.
350 West Ash Street, #103
San Diego, CA 92101
619-955-5285
jennifer@oliveprsolutions.com
http://www.oliveprsolutions.com

This release was published on openPR.